Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.28 +0.1%	$0.26	$0.20 ▼ $1.48	$73.31M	2.86	1.82 million shs	539,668 shs
EPIX ESSA Pharma	$1.61 -4.7%	$1.65	$1.40 ▼ $7.88	$71.47M	1.69	339,751 shs	372,214 shs
JSPR Jasper Therapeutics	$4.77	$4.53	$3.13 ▼ $26.84	$71.66M	2.74	292,578 shs	132,289 shs
MTEX Mannatech	$9.72 +2.3%	$9.77	$6.75 ▼ $16.49	$18.47M	1.06	4,442 shs	238 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+0.07%	-2.44%	+5.65%	-52.25%	-73.30%
EPIX ESSA Pharma	-4.73%	-2.42%	-9.04%	-5.29%	-74.80%
JSPR Jasper Therapeutics	0.00%	-5.36%	+0.85%	-17.76%	-80.06%
MTEX Mannatech	-1.37%	+5.25%	-13.64%	-14.52%	+26.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.1239 of 5 stars	4.2	4.0	3.8	0.8	0.0
EPIX ESSA Pharma	1.9438 of 5 stars	2.0	3.0	3.1	2.5	1.3
JSPR Jasper Therapeutics	2.5008 of 5 stars	3.5	2.0	3.6	1.7	0.6
MTEX Mannatech	0.8975 of 5 stars	0.0	5.0	2.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.43	Hold	$1.52	441.68% Upside
EPIX ESSA Pharma	2.00	Hold	$2.00	24.22% Upside
JSPR Jasper Therapeutics	3.00	Buy	$62.22	1,204.45% Upside
MTEX Mannatech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MTEX, EPIX, JSPR, and ADAP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/13/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/26/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.75
3/21/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $1.50
3/21/2025	ADAP Adaptimmune Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$3.15 ➝ $1.40
3/11/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$179.64M	0.41	N/A	N/A	$0.17 per share	1.65
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.68 per share	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$7.03 per share	N/A
MTEX Mannatech	$115.04M	0.16	N/A	N/A	$5.64 per share	1.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.27	N/A	N/A	N/A	-25.43%	-74.15%	-15.09%	8/11/2025 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.63	N/A	N/A	N/A	N/A	-24.61%	-23.87%	8/4/2025 (Estimated)
JSPR Jasper Therapeutics	-$64.46M	-$5.24	N/A	N/A	N/A	N/A	-67.64%	-58.53%	8/12/2025 (Estimated)
MTEX Mannatech	-$2.24M	-$0.10	N/A	∞	N/A	-1.26%	-15.62%	-3.76%	8/11/2025 (Estimated)

Latest MTEX, EPIX, JSPR, and ADAP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/13/2025	Q1 2025	MTEX Mannatech	N/A	-$0.80	N/A	-$0.80	N/A	$26.56 million
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q2 2025	EPIX ESSA Pharma	-$0.19	-$0.14	+$0.05	-$0.14	N/A	N/A
3/26/2025	Q4 2024	MTEX Mannatech	N/A	$1.20	N/A	$1.20	N/A	$29.01 million
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
MTEX Mannatech	$0.20	2.06%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
EPIX ESSA Pharma	N/A	33.12	33.12
JSPR Jasper Therapeutics	N/A	7.61	7.61
MTEX Mannatech	0.44	1.25	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
EPIX ESSA Pharma	75.12%
JSPR Jasper Therapeutics	79.85%
MTEX Mannatech	12.98%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
EPIX ESSA Pharma	15.50%
JSPR Jasper Therapeutics	2.70%
MTEX Mannatech	41.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	261.52 million	224.05 million	Optionable
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.60 million	Optionable
MTEX Mannatech	250	1.90 million	1.10 million	Not Optionable

MTEX, EPIX, JSPR, and ADAP Headlines

Recent News About These Companies

Mannatech (NASDAQ:MTEX) Now Covered by Analysts at Wall Street Zen

May 23, 2025 | americanbankingnews.com

Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

May 21, 2025 | businesswire.com

Mannatech Reports Financial Results for First Quarter 2025

May 13, 2025 | businesswire.com

Astronova outlines fiscal 2026 growth targets driven by aerospace and PI segment advancements

April 14, 2025 | msn.com

Mannatech Reports Fourth Quarter 2024 Financial Results

March 26, 2025 | businesswire.com

Mannatech Stock Soars to 52-Week High, Hits $16 Mark

January 30, 2025 | msn.com

Mannatech names Robert Toth vice chairman of the board

November 27, 2024 | markets.businessinsider.com

Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

November 26, 2024 | businesswire.com

Mannatech Inc. Q3 Earnings Summary

November 13, 2024 | markets.businessinsider.com

Mannatech Reports Financial Results for Third Quarter 2024

November 12, 2024 | businesswire.com

Trading (MTEX) With Integrated Risk Controls

October 17, 2024 | news.stocktradersdaily.com

(MTEX) Investment Analysis

October 6, 2024 | news.stocktradersdaily.com

Mannatech, Incorporated (NASDAQ:MTEX) Director Sells $126,232.00 in Stock

September 12, 2024 | insidertrades.com

Director Tyler Rameson Acquires 16,288 Shares of Mannatech Inc (MTEX)

September 11, 2024 | finance.yahoo.com

(MTEX) Trading Signals

August 19, 2024 | news.stocktradersdaily.com

Mannatech Reports Financial Results for Second Quarter 2024

August 13, 2024 | finance.yahoo.com

How To Trade (MTEX)

July 29, 2024 | news.stocktradersdaily.com

(MTEX) Long Term Investment Analysis

July 19, 2024 | news.stocktradersdaily.com

MTEX Stock Earnings: Mannatech Reported Results for Q1 2024

May 15, 2024 | investorplace.com

Mannatech Reports Financial Results for First Quarter 2024

May 14, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTEX, EPIX, JSPR, and ADAP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.28 +0.00 (+0.07%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$0.29 +0.01 (+4.89%)

As of 05/27/2025 07:54 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ESSA Pharma NASDAQ:EPIX

$1.61 -0.08 (-4.73%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.67 +0.06 (+3.73%)

As of 05/27/2025 05:41 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Jasper Therapeutics NASDAQ:JSPR

$4.77 0.00 (0.00%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$4.80 +0.03 (+0.61%)

As of 05/27/2025 07:55 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Mannatech NASDAQ:MTEX

$9.72 +0.22 (+2.26%)

Closing price 05/27/2025 03:50 PM Eastern

Extended Trading

$9.72 +0.01 (+0.05%)

As of 05/27/2025 06:00 PM Eastern

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time